All information products included in https://us-cert.cisa.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.
1. EXECUTIVE SUMMARY
- CVSS v3 7.8
- ATTENTION: Low skill level to exploit
- Vendor: Change Healthcare
- Equipment: Change Healthcare Cardiology, Horizon Cardiology, McKesson Cardiology
- Vulnerability: Incorrect Default Permissions
2. RISK EVALUATION
Successful exploitation of this vulnerability could allow a locally authenticated user to insert specially crafted files that could result in arbitrary code execution.
3. TECHNICAL DETAILS
3.1 AFFECTED PRODUCTS
The following Change Healthcare Cardiology Devices, are affected:
- Horizon Cardiology 11.x and earlier
- Horizon Cardiology 12.x
- McKesson Cardiology 13.x
- McKesson Cardiology 14. x
- Change Healthcare Cardiology 14.1.x
3.2 VULNERABILITY OVERVIEW
Insecure file permissions in the default installation may allow an attacker with local system access to execute unauthorized arbitrary code.
- CRITICAL INFRASTRUCTURE SECTORS: Healthcare and Public Health
- COUNTRIES/AREAS DEPLOYED: Worldwide
- COMPANY HEADQUARTERS LOCATION: United States
Alfonso Powers and Bradley Shubin of Asante Information Security reported this vulnerability to Change Healthcare.
Change Healthcare recommends users of the affected versions contact Change Healthcare Support as soon as possible to arrange installation of the supplied patch; To contact Change Healthcare Support please call:
- U.S./Canada 1-877-654-4366
- International Toll Free – 972-37698000 ext. 1
CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
- Minimize network exposure for all control system devices and/or systems.
- Locate medical devices behind firewalls and isolate them where possible.
- Restrict system access to authorized personnel only and follow a least privilege approach.
- Apply defense-in-depth strategies.
- Disable any unnecessary accounts, protocols and services.
- Where additional information is needed, refer to existing cybersecurity in medical device guidance issued by the FDA at the following location:
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage on us-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.
CISA also recommends that users take the following measures to protect themselves from social engineering attacks:
- Do not click web links or open unsolicited attachments in email messages.
- Refer to Recognizing and Avoiding Email Scams for more information on avoiding email scams.
- Refer to Avoiding Social Engineering and Phishing Attacks for more information on social engineering attacks.
No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.
For any questions related to this report, please contact the CISA at:
Toll Free: 1-888-282-0870
CISA continuously strives to improve its products and services. You can help by choosing one of the links below to provide feedback about this product.
Please share your thoughts.
We recently updated our anonymous product survey; we'd welcome your feedback.